Related Experiment Video

Updated: May 28, 2026

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

A mechanism for synergy with combined mTOR and PI3 kinase inhibitors

Shujie Yang1, Xue Xiao, Xiangbing Meng

  • 1Department of Obstetrics & Gynecology, The University of Iowa, Iowa City, Iowa, United States of America.

Plos One
|November 1, 2011
PubMed

Insights

Combining PI3K and mTORC1 inhibitors overcomes cancer resistance by blocking compensatory survival pathways. This combination therapy enhances cell death and expands potential treatment options for various tumor types.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling Pathways

Background:

  • Dysregulation of mammalian target of rapamycin (mTOR) signaling is implicated in human cancers, especially those with tumor suppressor PTEN loss.
  • Current mTORC1 inhibitors like temsirolimus show limited efficacy alone and can induce resistance by activating upstream pathways (mTORC2, Akt).
  • Tumors not reliant on PI3K/Akt/mTOR signaling exhibit primary resistance to these inhibitors.

Purpose of the Study:

  • To test if combining a PI3K inhibitor with temsirolimus synergistically inhibits cancer cell growth.
  • To elucidate the mechanism of combinatorial synergy between PI3K and mTORC1 inhibitors.
  • To determine if this combination therapy overcomes resistance mechanisms associated with PTEN status.

Main Methods:

  • Utilized proliferation assays to assess the effects of BEZ235 (dual PI3K/mTOR inhibitor) or ZSTK474 (pan PI3K inhibitor) in combination with temsirolimus.
  • Performed molecular profiling to analyze signaling pathway activation, including Akt phosphorylation and 4E-BP1 activity.
  • Evaluated cell cycle distribution, cell death mechanisms (autophagy, apoptosis), and p27 expression.

Main Results:

  • Combinations of PI3K inhibitors (BEZ235 or ZSTK474) with temsirolimus synergistically inhibited cancer cell growth.
  • Co-treatment induced G0/G1 cell cycle arrest, increased p27 expression, and triggered cell death via autophagy and apoptosis.
  • The combination therapy prevented compensatory Akt phosphorylation, enhancing cell death irrespective of PTEN status, and completely blocked 4E-BP1 phosphorylation, unlike temsirolimus alone.

Conclusions:

  • Adding a PI3K inhibitor to temsirolimus overcomes cellular resistance to mTORC1 inhibitors.
  • This combinatorial approach demonstrates synergistic efficacy regardless of PTEN status, broadening the range of responsive tumors.
  • The findings suggest a promising therapeutic strategy for expanding the clinical utility of mTORC1 inhibitors in cancer treatment.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...